Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
WeWork, a prized startup just four years ago but now a micro-cap, and other penny stocks such as Amyris and Proterra are the latest focus of speculative bets from retail traders, with shares of the fi...
Amyris (NASDAQ: AMRS ) stock is rising higher on Friday with heavy trading after the biotechnology company filed for bankruptcy. AMRS stock is bouncing back after the company's stock took a beating o...
Synthetic biotechnology company Amyris filed for Chapter 11 bankruptcy protection as it restructures, leading its share price to drop more than 70% in early trading Thursday....
Amyris (NASDAQ: AMRS ) stock is falling on Thursday after the company filed for Chapter 11 bankruptcy protection. According to a press release from Amyris, the company is entering bankruptcy to facil...
Voluntary Chapter 11 Commenced to Finalize Consensual Go-Forward Plan for Amyris' Core Business $190 Million Financing Commitment from Foris Ventures to Support Day-to-Day Operations EMERYVILLE, Calif...
Cash-strapped specialty renewable products developer Amyris remains on life support by largest shareholder and creditor John Doerr. In recent months, Doerr has provided another $157.5 million in secur...
Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category....
Not all low-priced stocks are appealing for investment, as some remain too unpredictable even at a lower buy-in price. This is a mixed bag and investors should do a deep analysis before investing in m...
The resignation of Amyris' CEO is likely to be viewed as a positive by many, but the implications of this are negative. Management turnover and the engagement of a consulting firm are not signs of a h...
